Alnylam price target raised to $535 from $459 at Truist

Truist raised the firm’s price target on Alnylam (ALNY) to $535 from $459 and keeps a Buy rating on the shares ahead of its Q3 results. The firm has increased its Q3 Amvuttra sales estimate to $690M and also revised its forward estimates higher to reflect carry through from the strong early adoption and more rapid adoption as a first line agent than previously expected based on feedback from prescribers in the quarter who indicated extracardiac manifestations of ATTR-CM are more widespread than previously appreciated, the analyst tells investors in a research note.

Elevate Your Investing Strategy:

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on ALNY:

Disclaimer & DisclosureReport an Issue

Alnylam and Regeneron Join Forces in Promising Alzheimer’s Study Alnylam price target raised to $475 from $405 at Morgan Stanley Alnylam price target raised to $495 from $441 at Stifel Alnylam Pharma Secures $500M Credit Agreement Alnylam doses first patient in ZENITH trial

View Comments